Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 108
- Registration Number
- NCT02291783
- Locations
- 🇬🇧
Parexel Early Phase Clinical Unit, Harrow, Middlesex, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath